These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 34066420)

  • 1. Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing
    Gaibani P; Lombardo D; Bussini L; Bovo F; Munari B; Giannella M; Bartoletti M; Viale P; Lazzarotto T; Ambretti S
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34066420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology and In Vitro Activity of Ceftazidime/Avibactam, Meropenem/Vaborbactam and Imipenem/Relebactam against
    Bovo F; Lombardo D; Lazzarotto T; Ambretti S; Gaibani P
    Antibiotics (Basel); 2022 Nov; 11(11):. PubMed ID: 36421265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of Bloodstream Infection due to a KPC-Producing Klebsiella Pneumoniae Resistant to Imipenem/Relebactam in a Hematological Patient.
    Gaibani P; Bussini L; Amadesi S; Bartoletti M; Bovo F; Lazzarotto T; Viale P; Ambretti S
    Microorganisms; 2022 Apr; 10(4):. PubMed ID: 35456827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem/vaborbactam activity
    Romanelli F; Stolfa S; Morea A; Ronga L; Prete RD; Chironna M; Santacroce L; Mosca A
    Future Microbiol; 2021 Nov; 16():1261-1266. PubMed ID: 34674551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro-obtained meropenem-vaborbactam resistance mechanisms among clinical Klebsiella pneumoniae carbapenemase-producing K. pneumoniae isolates.
    Findlay J; Poirel L; Nordmann P
    J Glob Antimicrob Resist; 2023 Mar; 32():66-71. PubMed ID: 36649860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of
    Rogers TM; Kline EG; Griffith MP; Jones CE; Rubio AM; Squires KM; Shields RK
    JAC Antimicrob Resist; 2023 Apr; 5(2):dlad022. PubMed ID: 36968951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome characterization of a Klebsiella pneumoniae co-producing OXA-181 and KPC-121 resistant to ceftazidime/avibactam, meropenem/vaborbactam, imipenem/relebactam and cefiderocol isolated from a critically ill patient.
    Gaibani P; Amadesi S; Lazzarotto T; Ambretti S
    J Glob Antimicrob Resist; 2022 Sep; 30():262-264. PubMed ID: 35777673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
    Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.
    Sun D; Rubio-Aparicio D; Nelson K; Dudley MN; Lomovskaya O
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 29038260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates.
    Gaibani P; Lewis RE; Volpe SL; Giannella M; Campoli C; Landini MP; Viale P; Re MC; Ambretti S
    Int J Infect Dis; 2017 Dec; 65():1-3. PubMed ID: 28951106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased
    Gaibani P; Bianco G; Amadesi S; Boattini M; Ambretti S; Costa C
    Antimicrob Agents Chemother; 2022 May; 66(5):e0019122. PubMed ID: 35416711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
    Tsivkovski R; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target
    Hayden DA; White BP; Bennett KK
    J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560
    [No Abstract]   [Full Text] [Related]  

  • 16. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
    Oliva A; Al Ismail D; Arcari G; Miele MC; Casali E; Sacco F; Volpicelli L; De Angelis M; Mascellino MT; Cancelli F; Raponi G; Carattoli A; Venditti M
    J Glob Antimicrob Resist; 2023 Jun; 33():321-327. PubMed ID: 37086891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing
    Tumbarello M; Raffaelli F; Cascio A; Falcone M; Signorini L; Mussini C; De Rosa FG; Losito AR; De Pascale G; Pascale R; Giacobbe DR; Oliva A; Farese A; Morelli P; Tiseo G; Meschiari M; Del Giacomo P; Montagnani F; Fabbiani M; Vargas J; Spanu T; Bassetti M; Venditti M; Viale P
    JAC Antimicrob Resist; 2022 Mar; 4(1):dlac022. PubMed ID: 35265842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant
    Belati A; Bavaro DF; Diella L; De Gennaro N; Di Gennaro F; Saracino A
    Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.
    Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.